1628 related articles for article (PubMed ID: 32253759)
21. Detectable Serum Severe Acute Respiratory Syndrome Coronavirus 2 Viral Load (RNAemia) Is Closely Correlated With Drastically Elevated Interleukin 6 Level in Critically Ill Patients With Coronavirus Disease 2019.
Chen X; Zhao B; Qu Y; Chen Y; Xiong J; Feng Y; Men D; Huang Q; Liu Y; Yang B; Ding J; Li F
Clin Infect Dis; 2020 Nov; 71(8):1937-1942. PubMed ID: 32301997
[TBL] [Abstract][Full Text] [Related]
22. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Brescia, Italy.
Toniati P; Piva S; Cattalini M; Garrafa E; Regola F; Castelli F; Franceschini F; Airò P; Bazzani C; Beindorf EA; Berlendis M; Bezzi M; Bossini N; Castellano M; Cattaneo S; Cavazzana I; Contessi GB; Crippa M; Delbarba A; De Peri E; Faletti A; Filippini M; Filippini M; Frassi M; Gaggiotti M; Gorla R; Lanspa M; Lorenzotti S; Marino R; Maroldi R; Metra M; Matteelli A; Modina D; Moioli G; Montani G; Muiesan ML; Odolini S; Peli E; Pesenti S; Pezzoli MC; Pirola I; Pozzi A; Proto A; Rasulo FA; Renisi G; Ricci C; Rizzoni D; Romanelli G; Rossi M; Salvetti M; Scolari F; Signorini L; Taglietti M; Tomasoni G; Tomasoni LR; Turla F; Valsecchi A; Zani D; Zuccalà F; Zunica F; Focà E; Andreoli L; Latronico N
Autoimmun Rev; 2020 Jul; 19(7):102568. PubMed ID: 32376398
[TBL] [Abstract][Full Text] [Related]
23. Tocilizumab for severe COVID-19 pneumonia: Case series of 5 Australian patients.
West TA; Malik S; Nalpantidis A; Tran T; Cannon C; Bhonagiri D; Chan K; Cheong E; Wan Sai Cheong J; Cheung W; Choudhury F; Ernest D; Farah CS; Fernando S; Kanapathipillai R; Kol M; Murfin B; Naqvi H; Shah A; Wagh A; Ojaimi S; Frankum B; Riminton S; Keat K
Int J Rheum Dis; 2020 Aug; 23(8):1030-1039. PubMed ID: 32881350
[TBL] [Abstract][Full Text] [Related]
24. Effective treatment of severe COVID-19 patients with tocilizumab.
Xu X; Han M; Li T; Sun W; Wang D; Fu B; Zhou Y; Zheng X; Yang Y; Li X; Zhang X; Pan A; Wei H
Proc Natl Acad Sci U S A; 2020 May; 117(20):10970-10975. PubMed ID: 32350134
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of tocilizumab in patients with COVID-19 ARDS undergoing noninvasive ventilation.
Menzella F; Fontana M; Salvarani C; Massari M; Ruggiero P; Scelfo C; Barbieri C; Castagnetti C; Catellani C; Gibellini G; Falco F; Ghidoni G; Livrieri F; Montanari G; Casalini E; Piro R; Mancuso P; Ghidorsi L; Facciolongo N
Crit Care; 2020 Sep; 24(1):589. PubMed ID: 32993751
[TBL] [Abstract][Full Text] [Related]
26. Hydroxychloroquine and tocilizumab therapy in COVID-19 patients-An observational study.
Ip A; Berry DA; Hansen E; Goy AH; Pecora AL; Sinclaire BA; Bednarz U; Marafelias M; Berry SM; Berry NS; Mathura S; Sawczuk IS; Biran N; Go RC; Sperber S; Piwoz JA; Balani B; Cicogna C; Sebti R; Zuckerman J; Rose KM; Tank L; Jacobs LG; Korcak J; Timmapuri SL; Underwood JP; Sugalski G; Barsky C; Varga DW; Asif A; Landolfi JC; Goldberg SL
PLoS One; 2020; 15(8):e0237693. PubMed ID: 32790733
[TBL] [Abstract][Full Text] [Related]
27. Lack of tocilizumab effect on mortality in COVID19 patients.
Holt GE; Batra M; Murthi M; Kambali S; Santos K; Bastidas MVP; Asif H; Haddadi S; Arias S; Mirsaeidi M
Sci Rep; 2020 Oct; 10(1):17100. PubMed ID: 33051534
[TBL] [Abstract][Full Text] [Related]
28. Efficacy of Hydroxychloroquine and Tocilizumab in Patients With COVID-19: Single-Center Retrospective Chart Review.
Roomi S; Ullah W; Ahmed F; Farooq S; Sadiq U; Chohan A; Jafar M; Saddique M; Khanal S; Watson R; Boigon M
J Med Internet Res; 2020 Sep; 22(9):e21758. PubMed ID: 32784192
[TBL] [Abstract][Full Text] [Related]
29. Using IL-2R/lymphocytes for predicting the clinical progression of patients with COVID-19.
Hou H; Zhang B; Huang H; Luo Y; Wu S; Tang G; Liu W; Mao L; Mao L; Wang F; Sun Z
Clin Exp Immunol; 2020 Jul; 201(1):76-84. PubMed ID: 32365221
[TBL] [Abstract][Full Text] [Related]
30. First case of drug-induced liver injury associated with the use of tocilizumab in a patient with COVID-19.
Muhović D; Bojović J; Bulatović A; Vukčević B; Ratković M; Lazović R; Smolović B
Liver Int; 2020 Aug; 40(8):1901-1905. PubMed ID: 32478465
[TBL] [Abstract][Full Text] [Related]
31. Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors.
Han H; Ma Q; Li C; Liu R; Zhao L; Wang W; Zhang P; Liu X; Gao G; Liu F; Jiang Y; Cheng X; Zhu C; Xia Y
Emerg Microbes Infect; 2020 Dec; 9(1):1123-1130. PubMed ID: 32475230
[TBL] [Abstract][Full Text] [Related]
32. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
[TBL] [Abstract][Full Text] [Related]
33. Tocilizumab, an Exploratory Treatment for Severe COVID-19 Patients.
Wang Y; Chen Y; Zhou X
Can J Infect Dis Med Microbiol; 2022; 2022():6375870. PubMed ID: 35308307
[TBL] [Abstract][Full Text] [Related]
34. The Combined Use of Tocilizumab and Hemoadsorption in a Patient with SARS-COV-2-19-Associated Pneumonia: A Case Report.
Berlot G; Tomasini A; Roman Pognuz E; Randino A; Chiella F; La Fata C; Piva M; Amato P; di Maso V; Bianco F; Gerini U; Tomietto P; Trenti T
Nephron; 2020; 144(9):459-462. PubMed ID: 32694244
[TBL] [Abstract][Full Text] [Related]
35. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
[TBL] [Abstract][Full Text] [Related]
36. Off-label use of tocilizumab for the treatment of SARS-CoV-2 pneumonia in Milan, Italy.
Morena V; Milazzo L; Oreni L; Bestetti G; Fossali T; Bassoli C; Torre A; Cossu MV; Minari C; Ballone E; Perotti A; Mileto D; Niero F; Merli S; Foschi A; Vimercati S; Rizzardini G; Sollima S; Bradanini L; Galimberti L; Colombo R; Micheli V; Negri C; Ridolfo AL; Meroni L; Galli M; Antinori S; Corbellino M
Eur J Intern Med; 2020 Jun; 76():36-42. PubMed ID: 32448770
[TBL] [Abstract][Full Text] [Related]
37. Preemptive interleukin-6 blockade in patients with COVID-19.
Guillén L; Padilla S; Fernández M; Agulló V; García JA; Telenti G; García-Abellán J; Botella Á; Gutiérrez F; Masiá M
Sci Rep; 2020 Oct; 10(1):16826. PubMed ID: 33033405
[TBL] [Abstract][Full Text] [Related]
38. IL-6-based mortality risk model for hospitalized patients with COVID-19.
Laguna-Goya R; Utrero-Rico A; Talayero P; Lasa-Lazaro M; Ramirez-Fernandez A; Naranjo L; Segura-Tudela A; Cabrera-Marante O; Rodriguez de Frias E; Garcia-Garcia R; Fernández-Ruiz M; Aguado JM; Martinez-Lopez J; Lopez EA; Catalan M; Serrano A; Paz-Artal E
J Allergy Clin Immunol; 2020 Oct; 146(4):799-807.e9. PubMed ID: 32710975
[TBL] [Abstract][Full Text] [Related]
39. Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality.
Zhang C; Wu Z; Li JW; Zhao H; Wang GQ
Int J Antimicrob Agents; 2020 May; 55(5):105954. PubMed ID: 32234467
[TBL] [Abstract][Full Text] [Related]
40. Factors significantly associated with COVID-19 severity in symptomatic patients: A retrospective single-center study.
Hirashima T; Arai T; Kitajima H; Tamura Y; Yamada T; Hashimoto S; Morishita H; Minamoto S; Kawashima K; Kashiwa Y; Kameda M; Takeshita T; Suzuki H; Matsuoka H; Yamaguchi S; Tanaka T; Nagai T
J Infect Chemother; 2021 Jan; 27(1):76-82. PubMed ID: 33051144
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
